A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis

Natalizumab, an anti-alpha4 integrin antibody, significantly reduces the number of visibly enhancing multiple sclerosis (MS) lesions. In this substudy of a 2-year trial of natalizumab monotherapy versus placebo, contrast-enhanced imaging investigated for subtle blood brain barrier (BBB) leakage in r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neurology Jg. 254; H. 3; S. 306 - 314
Hauptverfasser:	Soon, Derek, Altmann, Daniel R., Fernando, Kryshani T.M., Giovannoni, Garin, Barkhof, Frederick, Polman, Chris H., O’Connor, Paul, Gray, Bruce, Panzara, Michael, Miller, David H.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Berlin Springer 01.03.2007 Springer Nature B.V
Schlagworte:	Adult Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biological and medical sciences Blood-Brain Barrier - drug effects Case-Control Studies Double-Blind Method Female Follow-Up Studies Gadolinium DTPA Humans Immunomodulators Magnetic Resonance Imaging - methods Male Medical sciences Middle Aged Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - pathology Natalizumab Neurology Pharmacology. Drug treatments Statistics, Nonparametric Multiple sclerosis Nervous system diseases Natalizumab Central nervous system disease Central nervous system Placebo Blood brain barrier Tysabri·BBB·MS Encephalon Inflammatory disease
ISSN:	0340-5354, 1432-1459
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!